Related Experiment Video
Updated: Aug 6, 2026
05:12
Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
Published on: June 23, 2023
Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study
Tamanna Basri1, Stephanie J Shea1, Adam Brantley1
1Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX.
Mayo Clinic Proceedings
|July 22, 2026
Summary
Glucagon-like peptide-1 receptor agonist (GLP-1RA) use was linked to reduced alcohol consumption in adults. However, this effect diminished when weight loss was considered, suggesting a connection between reduced alcohol intake and weight changes.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Addiction Research
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for type 2 diabetes and obesity.
- The impact of GLP-1RAs on non-metabolic behaviors, such as alcohol consumption, requires further investigation.
Purpose of the Study:
- To investigate the association between GLP-1RA initiation and changes in weekly alcohol intake among current adult drinkers.
- To explore whether weight change mediates the relationship between GLP-1RA use and alcohol consumption.
Main Methods:
- Retrospective analysis of 11,258 adult outpatients from the Cooper Clinic.
- Comparison of self-reported weekly alcohol intake changes between GLP-1RA users (n=256) and a control group (n=11,002).
- Linear mixed-effects modeling adjusted for covariates including time, age, sex, glucose, and weight.
Main Results:
- GLP-1RA treatment was associated with a significant reduction in weekly alcohol intake (-1.0 drinks/week, P=.002).
- This reduction was no longer statistically significant after adjusting for weight change (P=.10).
Conclusions:
- GLP-1RA treatment is associated with decreased alcohol intake in adults who drink.
- The observed reduction in alcohol consumption appears to be significantly influenced by concurrent weight loss.
- Findings suggest that weight reduction may play a key role in the effect of GLP-1RAs on alcohol use.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...